Doximity Inc
NYSE:DOCS
Legen Sie fest, zu welchem Kurs Sie kaufen würden. Wir helfen Ihnen, bereit zu bleiben.
|
Doximity Inc
NYSE:DOCS
|
US |
|
Nextensa NV
LSE:0NUT
|
BE |
|
S
|
Shenyang Jinshan Energy Co Ltd
SSE:600396
|
CN |
|
Aurea SA
PAR:AURE
|
FR |
|
A
|
Assystem SA
XBER:BZ1
|
FR |
|
I
|
Industrivarden AB
SWB:IDVA
|
SE |
|
A
|
AUTO1 Group SE
XMUN:AG1
|
DE |
|
Z
|
Zalando SE
F:ZAL
|
DE |
|
MRF Ltd
NSE:MRF
|
IN |
|
S
|
Sumitomo Corp
XBER:SUMA
|
JP |
|
F
|
freenet AG
XMUN:FNTN
|
DE |
|
S
|
Sonoco Products Co
F:SNS
|
US |
|
O
|
O'Reilly Automotive Inc
SWB:OM6
|
US |
|
Swedbank AB
F:FRY
|
SE |
|
Schibsted ASA
OSE:SCHA
|
NO |
Doximity Inc
Doximity is a digital network for medical professionals in the United States, especially doctors, nurses, and other clinicians. Its main products are a professional social network, messaging and telehealth tools, electronic faxing and workflow apps, and a news and reference feed tailored to healthcare workers. The company’s platform helps clinicians communicate with one another, manage patient-related tasks, and stay connected to medical information in one place. Doximity makes money mainly by selling access to its audience and workflow tools. Pharmaceutical companies, health systems, and other healthcare businesses pay to reach verified clinicians with targeted advertising, sponsorships, and recruiting or communications products. In effect, Doximity sits between the healthcare workforce and the companies that want to market to, hire, or communicate with that workforce. What makes the business unusual is that it is not a hospital system, insurer, or drug maker; it is a professional utility built around trusted identity and daily use by clinicians. That gives it a specialized role in healthcare communications and physician engagement. Its value comes from being a closed, credentialed network where the users are medical professionals and the customers are organizations that need direct access to them.
Doximity is a digital network for medical professionals in the United States, especially doctors, nurses, and other clinicians. Its main products are a professional social network, messaging and telehealth tools, electronic faxing and workflow apps, and a news and reference feed tailored to healthcare workers. The company’s platform helps clinicians communicate with one another, manage patient-related tasks, and stay connected to medical information in one place.
Doximity makes money mainly by selling access to its audience and workflow tools. Pharmaceutical companies, health systems, and other healthcare businesses pay to reach verified clinicians with targeted advertising, sponsorships, and recruiting or communications products. In effect, Doximity sits between the healthcare workforce and the companies that want to market to, hire, or communicate with that workforce.
What makes the business unusual is that it is not a hospital system, insurer, or drug maker; it is a professional utility built around trusted identity and daily use by clinicians. That gives it a specialized role in healthcare communications and physician engagement. Its value comes from being a closed, credentialed network where the users are medical professionals and the customers are organizations that need direct access to them.
Revenue Beat: Doximity reported Q3 revenue of $185 million, up 10% year-over-year and exceeding the high end of guidance by 2%.
Strong Profitability: Adjusted EBITDA was $111 million with a 60% margin, also above guidance.
Record User Engagement: The platform surpassed 3 million registered members, representing over 85% of all U.S. physicians, with record active usage of workflow and AI products.
AI Adoption: Over 300,000 unique prescribers used Doximity's AI tools in Q3, and the company signed 100+ major health systems for its AI suite.
Guidance Unchanged: Despite Q3 outperformance, full-year guidance remains in line due to subdued Q4 expectations and higher AI infrastructure costs.
Pharma Budget Uncertainty: Delays in pharma clients' budget decisions, driven by new policy (MFN agreements), led to a slower Q4 revenue outlook but strong January bookings.
Optimistic Outlook: Management expects revenue growth to accelerate later in the year, aiming to exit calendar 2026 with double-digit growth and to commercialize AI products.
